Biopharma pharmaceutical company has sent UAH 6 million to buy equipment for the reference laboratory of the Public Health Center, which will be used to diagnose the coronavirus disease COVID-19.
As the company told Interfax-Ukraine, the equipment will allow quickly determining the presence or absence of the coronavirus disease pathogens in the samples obtained, using modern methods.
The first unit is Thermo Fisher Scitific Nucleic automatic acid extraction workstation with consumables for 20,000 samples. It helps prepare samples for analysis.
The second unit is Bio-Rad CFX 96 PCR detection system, which already directly determines the DNA of the virus, as well as test systems for it.
The equipment was purchased at the initiative of Biopharma co-owners Kostiantyn Yefymenko and Vasyl Khmelnytsky.
The Public Health Center said that the number of samples sent for verification is growing daily, so new equipment will allow quick testing.
The complex, which will be launched on Saturday, allows processing up to 100 samples in 60 minutes that is, up to 2,000 per day.
Earlier, Biopharma transferred the necessary equipment for UAH 5 million for the Bila Tserkva hospital three. In total, Biopharma sent more than UAH 11 million to support measures to combat the spread of COVID-19.
Biopharma, which is one of the ten largest Ukrainian manufacturers of the pharmaceutical industry and specializes in human blood plasma drugs, has submitted to the laboratories of the Public Health Center of the Ministry of Health of Ukraine equipment that will allow the presence and absence of samples to be determined quickly and by modern methods agents of coronavirus disease. This decision, in conjunction with entrepreneur Vasyl Khmelnytsky’s UFuture holding company, is a continuation of a series of social initiatives undertaken by Ukrainian entrepreneurs amid a coronavirus pandemic.
“The Center will become the main reference site that will monitor the correctness of diagnostics throughout Ukraine. In other words, samples from laboratories will be sent here to confirm or refute the diagnosis. Without the transferred equipment, effective control of coronavirus disease in Ukraine would be defective,” Kostiantyn Yefymenko, President of Biopharma, reported.
The first unit is the Nuclear Acid Extraction Equipment from Thermo Fisher Scitific with consumables for 20,000 samples. The equipment helps prepare samples for analysis. The second unit is the equipment of Bio-Rad CFX 96 for molecular genetic analysis by PCR for the presence of a DNA virus and a system test for the detection of COVID-19.
The total cost of the equipment exceeds six million UAH, its installation and startup is performed by the company “ALT Ukraine LTD”. The equipment allows to process up to 100 samples in 60 minutes and in total about 2 thousand analyzes per day.
“Business should do everything in its power to stop the spread of the coronavirus and bring Ukraine back to normal. First of all, we need quality and timely diagnostics. already hundreds of millions of hryvnias and assistance continues,” Vasyl Khmelnytsky, founder of UFuture, said.
In addition, UFuture purchased two lung ventilation devices and all materials for their operation for the amount of 1 million 700 thousand UAH to one of the hospitals in Kyiv, and Biopharma — equipment for Bila Tserkva city hospital №3 (reference infectious hospital for the Kyiv region) with an amount of five million UAH.
• two AR-203 artificial ventilation apparatus;
• AS-200 biochemical automatic analyzer;
• 3-Part DiffH 18 light hematology analyzer;
• EasyStat blood gas and electrolyte analyzer;
• BM1600 patient monitor with BM200 module;
• Laura Smart urine analyzer;
• two microscopes Micromed Fusion FS-7620.
The total cost of assistance from the holding companies is more than 12 million UAH. Also, masks and systems for rapid tests for the hospitals of Bila Tserkva will be purchased soon.
UFuture is a holding company of Ukrainian entrepreneur Vasyl Khmelnytsky that integrates his business and impact-investment projects. The company has a diversified portfolio of assets in the fields of real estate, infrastructure, industry, renewable energy, pharmaceuticals, and IT. Currently, UFuture’s assets are estimated at $550 million, and the total capitalization of the businesses it invested in is more than $1 billion.
Biopharma is a Ukrainian immunobiological pharmaceutical company that which specializes in the drugs of human blood plasma. The number of employees – more than 300 people. The company exports drugs to 36 countries. In 2019, the company opened in Bila Tserkva a “built from scratch” manufacturing facility, investing about $75 million. Its the only plant of its kind in Eastern Europe.
Managing Partner of Biopharma Kostiantyn Yefymenko is considering the possibility of building a lysine plant in Bila Tserkva (Kyiv region), which is used as a feed additive in animal husbandry.
“I now have two options. To build a Biopharma plant in India and Brazil or a lysine plant. I bought a 10 ha plot with a supply of 100 cubic meters of water per hour, Biopharma consumes 75 cubic meters per day, the plant is the equivalent to processing 120,000 tonnes of grain. With the supply of water, the problem is solved, I’ve already bought 10 hectares, I have already connected electricity … I lean toward the lysine plant in Bila Tserkva,” he said on the sidelines of the Kyiv International Economic Forum.
He noted that he had already invested $2 million in the project.
As reported, the German pharmaceutical company STADA buys the pharmaceutical business of prescription and over-the-counter drugs of the Biopharma manufacturer of blood-derived products. The transaction is expected to close in December 2019.
Biopharma Managing Partner Kostiantyn Yefymenko together with partner Vasyl Khmelnytsky and financial investors will focus on developing the Biopharma blood plasma processing business, developing a new Biopharma plasma fractionation plant and a network of modern blood collection centers, as well as expanding its presence in international markets.
Germany’s STADA pharmaceutical company is acquiring pharmaceutical business of prescription and OTC preparations of Biopharma blood product manufacturer. According to a STADA press release on Monday, Biopharma’s pharmaceutical business will become an integral part of STADA in Ukraine and has strong growth potential in the production of high-quality prescription and OTC drugs. The agreement provides for the acquisition of production facilities in the city of Bila Tserkva (Kyiv region).
Biopharma shareholders will preserve the company’s plasma processing business and focus on its development both in Ukraine and abroad. To acquire it STADA must obtain permission to merge in Ukraine.
The transaction is expected to close in December 2019.
STADA’s Ukrainian business will be led by newly appointed CEO Borys Labensky.
Biopharma President Kostyantyn Efymenko, together with partner Vasyl Khmelnytsky and financial investors, will focus on developing the Biopharma plasma processing business, developing the new Biopharma plasma fractionator and a network of modern blood collection centers and expanding its presence in international markets.
Biopharma, a top-ten pharmaceutical producer in Ukraine specializing in plasma-based, recombinant and other drugs, has officially opened its innovative fractionator in Bila Tserkva (Kyiv region), the only biopharmaceutical plant of its kind in Eastern Europe and the near region. There are no plasma fractionation plants in any neighboring countries – the closest are in Austria, South Africa and China. This unique plasma fractionation technology enables the plasma component of human blood to be processed to extract life-saving drugs, requires advanced research and development, GMP-certified equipment and facilities, and investments exceeding $75 million.
“September 20 will become a new page in the modern scientific and industrial history of Ukraine, as not just a new production facility was launched, – a new science-based industry was launched based on high technologies. This puts Ukraine on par with countries such as the USA, Austria, Germany and allows Ukraine to enter the world market with medicines, the production of which requires its own R&D base, high culture of production, development of donor infrastructure according with the highest standards. Today, Ukraine has proved that it is capable of that!” – Kostyantyn Efymenko, president of Biopharma group of companies emphasized.
Biopharma’s new facility is the first and only plasma fractionation plant in Ukraine that will have the capacity to process up to one million liters of plasma per year. This will fully meet the country’s internal needs for plasma-based drugs, which is an important element of national security of Ukraine. By replacing imported drugs with high-quality Ukraine-processed plasma products, Biopharma estimates that the country will save up to $100 million per year. In addition, the launch of the new plant will allow Biopharma to double the significant amount of local and state taxes paid, making the сompany the largest taxpayer in Bila Tserkva, contributing more than all local businesses combined.
“We believe in the high potential of Ukraine and its pharmaceutical industry in particular. Together with our partners, we haven’t stopped investing and, in the difficult times of the new history, continued to systematically develop the company. I am proud that Biopharma has mastered the advanced and very sophisticated technology that is available in few countries in the world. This is why we’ll be able to compete not only on the local market, but also on the global one”, – Vasyl Khmelnytsky, founder of UFuture, said.
Lenna Koszarny, Founding Partner and CEO, Horizon Capital, added: “Horizon Capital’s EEGF II Fund and Dutch development finance bank FMO invested in Biopharma in 2012 to address the serious issue of 120 tons of plasma thrown out each year not processed into life-saving drugs, because a plant like this did not exist in Ukraine. We were attracted by the vision of operating shareholder Kostyantyn Efymenko and through his leadership and commitment as well as the dedication of the Company’s committed shareholders and excellent management team, this vision has become a reality. In June 2015, Biopharma launched a state-of-the art greenfield non-plasma plant, and today, we are proud to launch the most modern plasma fractionation plant in Central and Eastern Europe and contribute to Biopharma’s success”.
The new plant is equipped with modern machinery produced by the world-known manufacturers such as Stilmas, Olsa, GEA Westfalia, General Electric healthcare, Pall, Steriline. It has three production lines for albumin, immunoglobulin and factor VIII drugs that are critical for victims of severe injuries and burns, for people fighting cancer, hemophilia, for pregnant women and other patients.
Linda Broekhuizen, Chief Investment Officer of FMO, says: “FMO congratulates the shareholders and management of Biopharma with the launch of the new fractionator plant. A great milestone that underlines the company’s entrepreneurial drive and commitment to investing in growth, even though the Ukrainian economy has undergone tremendous challenges. This state-of-the-art facility provides jobs and reduces dependence from imports, both healthy ingredients to further economic growth.”
The opening ceremony was attended by more than 1,000 guests, including government representatives, medical professionals, the business community from Ukraine and from over 20 countries.
Contact for the media: Tetyana Shvets, +38067 604 3 555.
Biopharma is a Ukrainian immunobiological pharmaceutical company that develops and manufactures drugs based on human blood, recombinant drugs, probiotics based on spore-forming bacteria and traditional drugs. The company produces about 20 million packages of drugs per year. The number of employees – more than 500 people. The company exports drugs to 36 countries. At least 4 times a year, Biopharma is a subject to quality review by foreign and Ukrainian auditors.
UFuture is a holding company of Ukrainian entrepreneur Vasyl Khmelnytsky that integrates his business and impact-investment projects. The Company has a diversified portfolio of assets in real estate, industry, infrastructure, renewable energy, pharmaceuticals, and IT. As of today, UFuture’s assets are estimated at $550 million with total capitalization of the businesses invested in exceeding $1 billion.
Horizon Capital is the leading private equity firm in Ukraine, backed by over 40 institutional investors in four funds with over $850 million in assets under management. Its Ukraine-focused funds have invested over $700 million in 140 companies employing over 52,000 people in Ukraine and neighboring countries. Horizon Capital is a value-added investor, backing visionary entrepreneurs leading transformational businesses in Ukraine and the near region.
FMO is the Dutch entrepreneurial development bank. As a leading impact investor, FMO supports sustainable private sector growth in developing countries and emerging markets by investing in ambitious projects and entrepreneurs. FMO believes that a strong private sector leads to economic and social development and has a close to 50-year proven track-record of empowering people to employ their skills and improve their quality of life. FMO focuses on three sectors that have high development impact: financial institutions, energy, and agribusiness, food & water. With a committed portfolio of EUR 9.7 billion spanning over 85 countries, FMO is one of the larger bilateral private sector developments banks globally.
The blood preparations manufacturer, Biopharma, at the end of September will officially open a fractionator plant in Bila Tserkva (Kyiv region).
As the company told Interfax-Ukraine, the construction and commissioning work lasted about four years. In total, the company invested more than $75 million in the construction of the plant.
The plant has installed equipment from global manufacturers in the industry: Stilmas, Olsa, GEA Westfalia, General Electric healthcare, Pall, and Steriline.
“This is the only this kind of plant in Eastern Europe. Our competitors are in Austria, South Africa and China. None of the neighboring countries has such production,” the company said.
For the official opening of the production Biopharma will hold an international conference entitled “Topical Issues of Industrial Production of Blood Products” with the participation of representatives of scientific, medical and regulatory institutions in the field of transfusion from more than 20 countries.
As reported, the plant will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Biopharma planned to put it into operation at the end of 2018.
Biopharma immunobiological pharmaceutical company is among the ten largest Ukrainian manufacturers of drugs. It produces more than 20 immunobiological preparations from donated blood plasma, preparations obtained by recombinant DNA technology and probiotics.